Vaxart, Inc.

NASDAQ:VXRT

$0.7141 USD

$0.01 (1.59%)

Volume
624.76K
Average Volume
1.81M
Market Capitalization
$162.44M
P/E Ratio
-2.25
Dividend Yield
0.00%
Price Target
$2.00
Year High
$1.54
Year Low
$0.52
Payout Ratio
$0.00
Current Ratio
$0.83

Industry, Sector & symbol

Stock Exchange NASDAQ Capital Market
CEO Mr. Steven Lo
Industry Biotechnology
Sector Healthcare
Current Symbol VXRT
CUSIP 92243A200
CIK 0000072444
Web https://vaxart.com
Phone 650 550 3500
Currency USD
Employees 109
Country US

Liquidity

Debt-to-Equity Ratio 0.27
Payout Ratio 0.00
Current Ratio 0.83
Quick Ratio 0.83
Cash Ratio 0.27

Sales & Book Value

Annual Sales $7.38M
Price / Sales 9.69
Cash Flow -0.23
Price / Cash Flow -3.16
Price / Book 2.37

Price Target and Rating

Average Stock Price Forecast $2.00
High Stock Price Forecast $2.00
Low Stock Price Forecast $2.00
Forecast Upside/Downside -64.30%
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 3 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.57
Trailing P/E Ratio -2.25
PEG Ratio -0.20
P/E Growth -0.20
Net Income $-82.46M
Net Margin -431.61%
Pretax Margin -430.07%
Return on Equity -110.46%
Return on Assets -43.40%

Financials Score

AltmanZ Score -4.30
Piotroski Score 3.00
Working Capital -13.91M
Total Assets 166.67M
Ebit -70.13M
Market Cap 162.44M
Total Liabilities 98.23M

Poll Results

About Vaxart, Inc. (NASDAQ:VXRT) Stock

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California. ...

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

2025-01-13 19:55:00

Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

2024-12-02 16:01:00

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart's COVID-19 vaccine candidate and 200 receiving an approved mRNA vaccine comparator.

VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates

2024-11-13 18:20:22

VAXART, INC. (VXRT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10.

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

2024-11-13 18:19:35

Vaxart, Inc. (NASDAQ:VXRT ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Senior Vice President and Chief Scientific Officer Phillip Lee - Chief Financial Officer Conference Call Participants Cheng Li - Oppenheimer Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings and welcome to the Vaxart Business Update and Third Quarter 2024 Financial Results Conference Call.

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

2024-11-13 16:01:00

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Frequently Asked Questions

What is the current Vaxart, Inc. (VXRT) stock price?

Vaxart, Inc.(NASDAQ:VXRT) stock price is $0.7141 in the last trading session. During the trading session, VXRT stock reached the peak price of $1.54 while $0.52 was the lowest point it dropped to. The percentage change in VXRT stock occurred in the recent session was 1.59% while the dollar amount for the price change in VXRT stock was $0.01.

VXRT's industry and sector of operation?

The NASDAQ listed VXRT is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of VXRT?

Dr. James F. Cummings M.D. | Chief Medical Officer
Ms. Shaily Jaini Garg | Senior Vice President of Clinical Development & Project Management
Mr. Edward B. Berg | Senior Vice President & General Counsel
Mr. Steven Lo | President, Chief Executive Officer & Director
Dr. Sean N. Tucker Ph.D. | Senior Vice President & Chief Scientific Officer

How many employees does VXRT have?

Number of VXRT employees currently stands at 109. VXRT operates from 170 Harbor Way, South San Francisco, CA 94080, US.

Link for VXRT official website?

Official Website of VXRT is: https://vaxart.com

How do I contact VXRT?

VXRT could be contacted at phone #650 550 3500 and can also be accessed through its website. VXRT operates from 170 Harbor Way, South San Francisco, CA 94080, US.

How many shares of VXRT are traded daily?

The average number of VXRT shares traded daily for last 3 months was 1.81M.

What is the market cap of VXRT currently?

The market value of VXRT currently stands at $162.44M with its latest stock price at $0.7141